Eylea, Eylea HD (aflibercept)

Eylea and Eylea HD intravitreal injections are covered only for the listed FDA‑approved ophthalmic indications (neovascular AMD, RVO‑related macular edema, DME, DR, ROP) and certain off‑label compendial neovascular ophthalmic conditions. Approval requires documentation of the qualifying diagnosis, administration by or under the supervision of an ophthalmologist, adherence to the indication‑specific dosing schedules, and is authorized for 12 months.

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.